Dr. Lior Shaltiel reports

EXOPTEN PRECLINICAL STUDY DEMONSTRATES SIGNIFICANT POTENTIAL FOR ENHANCING MOTOR FUNCTION, BLOOD FLOW, AND SPINAL CORD INJURY RECOVERY

Nurexone Biologic Inc. has successfully completed an important preclinical study toward its investigational new drug (IND) submission. The new study, which advances the company's path toward first-in-human trials, demonstrated that ExoPTEN treatment with different dose regimens led to both motor function recovery and significant improvements in blood flow at the site of spinal cord injury -- an essential factor in tissue healing and functional recovery.

"This preclinical study evaluated dosing regimens to provide efficacy data in support of our IND submission," said Dr. Tali Kizhner, director of R&D (research and development) at NurExone. "The results reinforce ExoPTEN's potential to enhance the body's natural repair mechanisms following spinal cord injury. Notably, the increased blood vessel size observed in treated subjects indicated improved circulation, which is crucial for oxygen and nutrient delivery to damaged tissues. These findings suggest that ExoPTEN has the potential to become a transformative therapeutic candidate, and we are eager to advance toward clinical trials."

Scientific publications and reach in the field have shown already that postinjury angiogenesis and vascular remodeling correlate with improved functional recovery in spinal cord injury models.

The study compared two dosing regimens of ExoPTEN: a single high dose on the day of surgery versus a lower dose administered over five consecutive days. Both treatment groups showed significant improvements in motor function recovery compared to the control group, as measured by the modified Basso, Beattie and Bresnahan (BBB) locomotor rating scale. Additionally, histological analysis revealed that ExoPTEN treatment significantly increased the average blood vessel size, suggesting improved circulation -- a critical factor in postinjury healing and functional restoration.

NurExone will continue to refine ExoPTEN's therapeutic profile as part of its continuing preclinical program, paving the way to IND submission and regulatory approval for first-in-human trials.

About Nurexone Biologic Inc.

Nurexone Biologic is a TSX Venture Exchange-, OTCQB- and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multibillion-dollar markets. Regulatory milestones, including orphan drug designation, facilitate the road map toward clinical trials in the United States and Europe. Commercially, the company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a United States subsidiary, to anchor its North American activity and growth strategy.

We seek Safe Harbor.